India's June wholesale prices fall for first time in 19 months

Chinese robotics startups AgiBot and Unitree are riding a wave of enterprise demand, securing a hefty 124 million yuan ($17.3 million) order from telecom giant China Mobile. The deal includes humanoid robots for tasks like customer service and logistics, signaling growing corporate adoption of advanced automation in China.

Editor’s Note: This isn’t just another tech deal—it’s a sign that humanoid robots are moving beyond labs and into real-world business use. With a heavyweight like China Mobile betting on them, these bots could soon become a common sight in industries from telecoms to retail. For China’s tech scene, it’s proof that homegrown robotics firms are gaining serious traction.

President Trump’s "One Big Beautiful Bill" – a sweeping package combining tax cuts and new spending – has just cleared Congress. Now, everyone’s wondering: what’s the real-world impact? Will it boost the economy or blow up the deficit? This isn’t just inside baseball; it’s a policy shake-up that could hit wallets, businesses, and government budgets for years.

Editor’s Note: Love it or hate it, this bill’s a big deal. It’s not just about political wins—it could reshape everything from your paycheck to how much the government spends on roads or healthcare. The debate isn’t just ideological; it’s about who actually benefits and what gets left behind. Buckle up.

UBS Chief Strategist Bhanu Baweja thinks investors are brushing off tariff risks way too casually. In a Bloomberg TV interview, he argued that markets are dead wrong to ignore the potential economic fallout from tariffs, even if they seem unfazed right now. Basically, he’s waving a red flag while everyone else shrugs.

Editor’s Note: If Baweja’s right, this could be one of those "calm before the storm" moments. Markets might be pricing in smooth sailing, but tariffs could still throw a wrench into supply chains, inflation, and corporate profits down the line. It’s a reminder that complacency can bite—especially when geopolitics are involved.

Hedge funds are making big moves—ditching bank stocks and snapping up consumer staples like groceries and household goods, according to Goldman Sachs. It looks like they’re betting on safer, recession-proof essentials while backing away from riskier financial sector plays.

Editor’s Note: This isn’t just about Wall Street shuffling papers—it’s a sign of where big money thinks the economy might be headed. If hedge funds are bailing on banks and stocking up on stuff people buy no matter what (think toothpaste and cereal), it suggests they’re bracing for tougher times. For everyday folks, it’s a peek into how the pros are hedging their bets.

Analyst firm H.C. Wainwright is sticking with its "Buy" recommendation for Abeona Therapeutics, even after the FDA rejected one of the company's key treatments. The firm seems confident Abeona can bounce back, suggesting this setback might just be a temporary hurdle rather than a dealbreaker.

Editor’s Note: For investors watching Abeona, this is a signal that not all hope is lost. FDA rejections can tank biotech stocks, but when analysts keep the faith, it often means there’s a path forward—maybe revised data, better trials, or a different approach. If you’re into high-risk, high-reward plays, this kind of resilience could be worth keeping an eye on.